Kausik Kumar Ray

Kausik Kumar Ray's AcademicInfluence.com Rankings

Kausik Kumar Ray

Medical

#2057

World Rank

#2454

Historical Rank

Cardiology

#174

World Rank

#179

Historical Rank

Pharmacology

#213

World Rank

#253

Historical Rank

medical Degrees

Kausik Kumar Ray

Philosophy

#6034

World Rank

#8996

Historical Rank

Logic

#3228

World Rank

#4354

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Kausik Kumar Ray's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Kausik Kumar Ray Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kausik Kumar Ray's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. (2013) (3012)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. (2010) (1978)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) (1817)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) (1786)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) (1770)
Major lipids, apolipoproteins, and risk of vascular disease. (2009) (1563)
Lipoprotein(a) as a cardiovascular risk factor: current status (2010) (1466)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials (2009) (1339)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011) (1099)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. (2011) (1065)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Low-density lipoproteins cause atherosclerotic cardiovascular disease (2018) (936)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (2017) (621)
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. (2008) (562)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (2015) (559)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) (545)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) (541)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) (470)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. (2020) (467)
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. (2010) (457)
Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. (2011) (449)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. (2014) (442)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. (2020) (424)
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol (2019) (370)
B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies (2009) (361)
Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) (356)
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. (2005) (341)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. (2020) (331)
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. (2005) (317)
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. (2012) (310)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (2015) (299)
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. (2014) (299)
Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. (1977) (296)
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. (2016) (292)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. (2020) (291)
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel (2017) (289)
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. (2005) (283)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. (2020) (256)
High-density lipoprotein and coronary heart disease: current and future therapies. (2010) (224)
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018) (221)
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk (2017) (216)
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial (2016) (212)
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia (2018) (183)
The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis (2012) (181)
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. (2015) (180)
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease (2020) (180)
Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies (2015) (175)
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. (2006) (173)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (2015) (167)
Mendelian Randomization Study of ACLY and Cardiovascular Disease (2019) (166)
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. (2016) (166)
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy (2019) (161)
Optimizing Cholesterol Treatment in Patients With Muscle Complaints. (2017) (161)
Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT–TIMI 22 (2009) (159)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel# (2017) (151)
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial (2018) (150)
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). (2018) (147)
Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome (2007) (146)
Familial hypercholesterolaemia: A global call to arms. (2015) (144)
Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population (2016) (139)
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. (2020) (133)
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. (2002) (130)
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. (2016) (130)
Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. (2015) (129)
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. (2005) (127)
Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. (2005) (127)
Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. (2015) (125)
The impact of statin therapy on plasma levels of von Willebrand factor antigen (2015) (124)
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials (2015) (123)
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration (2017) (121)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. (2019) (119)
Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. (2019) (115)
Determining When to Add Nonstatin Therapy: A Quantitative Approach. (2016) (113)
Association between statin use and plasma D-dimer levels (2015) (112)
Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial (2018) (108)
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD) (2011) (100)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1 (2018) (99)
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. (2014) (99)
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial (2017) (96)
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. (2013) (94)
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial (2018) (93)
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia (2020) (90)
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. (2014) (88)
Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. (2015) (88)
Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. (2016) (85)
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease (2018) (85)
Reductions in Atherogenic Lipids and Major Cardiovascular Events (2016) (85)
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial (2018) (82)
Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus (2014) (82)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. (2019) (81)
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. (2020) (81)
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? (2006) (79)
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. (2020) (79)
Advances in lipid-lowering therapy through gene-silencing technologies (2018) (78)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial (2020) (78)
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? (2005) (76)
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022) (75)
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and (2017) (74)
Leukocyte Telomere Length Is Associated With High-Risk Plaques on Virtual Histology Intravascular Ultrasound and Increased Proinflammatory Activity (2011) (70)
Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature. (2016) (69)
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) (2021) (68)
Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. (2006) (68)
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. (2021) (67)
‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies (2017) (67)
Inclisiran-New hope in the management of lipid disorders? (2019) (66)
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology (2004) (65)
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. (2019) (64)
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? (2013) (63)
Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care (2020) (63)
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. (2020) (61)
Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials (2016) (58)
Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials (2016) (57)
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. (2022) (56)
Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management (2015) (56)
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. (2005) (56)
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics (2019) (55)
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. (2019) (54)
The shortfall in long-term survival of patients with repaired thoracic or abdominal aortic aneurysms: retrospective case-control analysis of hospital episode statistics. (2013) (54)
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial (2018) (53)
Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. (2006) (53)
Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? (2018) (53)
Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. (2007) (52)
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). (2011) (52)
Inhibitory role of Acorus calamus in ferric chloride–induced epileptogenesis in rat (2007) (51)
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up (2017) (50)
Statin diabetogenicity: guidance for clinicians (2013) (50)
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. (2018) (49)
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. (2022) (48)
Central inhibitory effect of Moringa oleifera root extract: possible role of neurotransmitters. (2003) (47)
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. (2017) (47)
Cardiovascular risk prevention and all‐cause mortality in primary care patients with an abdominal aortic aneurysm (2016) (46)
Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. (2015) (46)
The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials. (2013) (44)
Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options (2019) (44)
Combination lipid-lowering therapy as first-line strategy in very high-risk patients. (2021) (44)
Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation (2004) (43)
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. (2020) (41)
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials (2013) (40)
Role of Bempedoic Acid in Clinical Practice (2021) (40)
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. (2021) (39)
Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans (2017) (39)
Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. (2013) (37)
Inclisiran for the treatment of dyslipidemia (2018) (36)
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. (2005) (36)
Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. (2018) (36)
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. (2019) (36)
Epidemiology of familial hypercholesterolaemia: Community and clinical. (2018) (36)
Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. (2006) (35)
Statin treatment and the risk of recurrent pulmonary embolism. (2013) (35)
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study (2022) (34)
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials (2005) (34)
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study (2022) (34)
Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines (2017) (34)
Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1. (2020) (34)
Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). (2006) (33)
Prediction of cardiovascular risk in patients with familial hypercholesterolaemia (2017) (32)
Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. (2015) (32)
Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1 (2016) (32)
Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries (2019) (32)
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study (2021) (30)
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. (2017) (30)
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?: CETP as a Target to Lower CVD Risk Suspension of Disbelief? (2015) (29)
Novel emerging therapies in atherosclerosis targeting lipid metabolism (2020) (28)
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. (2011) (27)
Coronary spasm in acute myocardial infarction (1998) (27)
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk (2017) (27)
Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. (2002) (26)
Triglycerides and residual risk. (2020) (26)
Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review (2020) (26)
New Approaches in Detection and Treatment of Familial Hypercholesterolemia (2015) (25)
Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). (2017) (25)
Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK (2016) (24)
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. (2019) (23)
Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey. (2016) (23)
The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta‐analysis of randomized controlled trials (2017) (22)
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? (2017) (21)
Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. (2015) (21)
Long‐term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta‐analysis of studies in the post‐reperfusion era (2017) (21)
Moving Toward the Next Paradigm for Cardiovascular Prevention. (2016) (21)
Cholesterol-Lowering Agents: Statins—For Everyone? (2019) (21)
Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy (2012) (20)
Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study (2017) (20)
Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment (2015) (19)
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies (2019) (19)
Recent trials of lipid lowering (2007) (19)
Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES (2018) (18)
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy (2013) (18)
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. (2017) (18)
Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential (2020) (18)
Intensive statin therapy in acute coronary syndromes (2008) (18)
Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe (2017) (18)
Coronary Artery Calcium to Improve the Efficiency of Randomized Controlled Trials in Primary Cardiovascular Prevention. (2020) (18)
Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. (2016) (17)
Low Density Lipoprotein Cholesterol–Lowering Strategies and Population Health (2020) (17)
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome (2021) (17)
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol (2020) (17)
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk (2018) (17)
Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. (2016) (16)
Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1 (2018) (16)
Role of 5-hydroxytryptamine in Moringa oleifera induced potentiation of pentobarbitone hypnosis in albino rats. (2004) (16)
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials (2022) (15)
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. (2020) (15)
32 TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE: EVIDENCE AND GUIDANCE FOR MANAGEMENT (2011) (15)
Intensive glucose lowering treatment in type 2 diabetes (2011) (14)
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. (2019) (14)
The year in cardiology: cardiovascular prevention. (2020) (14)
Coronary artery stenting in unstable angina pectoris: a comparison with stable angina pectoris (1999) (13)
Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials (2015) (13)
A review of statin use in patients with acute coronary syndrome in Western and Japanese populations (2013) (12)
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials (2022) (12)
Clinical implications and outcomes of the ORION Phase III trials. (2020) (12)
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. (2021) (12)
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. (2023) (11)
Familial Hypercholesterolemia: JACC Focus Seminar 4/4. (2021) (11)
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk (2018) (11)
The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes (2019) (11)
Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. (2021) (10)
Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials (2018) (10)
New prospects for PCSK9 inhibition? (2018) (10)
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial (2012) (10)
Radiation and Health Effects (2015) (10)
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). (2022) (10)
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes (2010) (10)
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. (2023) (9)
LDL-Cholesterol Lowering Strategies and Population Health - Time to Move to a Cumulative Exposure Model. (2020) (9)
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. (2021) (9)
Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies (2020) (9)
Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease (2018) (9)
Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. (2021) (9)
Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. (2005) (9)
PAEDIATRIC FAMILIAL HYPERCHOLESTEROLAEMIA SCREENING IN EUROPE - PUBLIC POLICY BACKGROUND AND RECOMMENDATIONS. (2022) (9)
The evolving role of CETP inhibition: beyond HDL cholesterol (2015) (9)
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial (2021) (9)
Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes (2007) (8)
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study (2021) (8)
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. (2019) (8)
Lipids and Lipoproteins in Risk Prediction. (2018) (8)
Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. (2017) (8)
The safety and clinical usefulness of dobutamine stress echocardiography among octogenarians (2014) (8)
Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. (2018) (8)
Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia? (2020) (8)
GENETIC TARGET VALIDATION FOR ATP-CITRATE LYASE INHIBITION (2017) (8)
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial (2021) (8)
C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). (2005) (7)
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. (2022) (7)
Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated? (2015) (7)
What imaging techniques should be used in primary versus secondary prevention for further risk stratification? (2017) (7)
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis (2022) (7)
Lipid Clinics Network. Rationale and design of the EAS global project. (2020) (7)
A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy (2019) (6)
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials (2020) (6)
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial (2022) (6)
Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. (2021) (6)
Statin and exercise prescription (2013) (6)
Improving the global care of familial hypercholesterolaemia: Starting the ball rolling. (2018) (6)
Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. (2021) (6)
Lp(a) and cardiovascular disease-Has the phoenix finally risen from the ashes? (2019) (5)
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab (2020) (5)
Effect of saxagliptin on renal outcome (2014) (5)
The past, present and future of lipidlowering therapy (2015) (5)
Familial hypercholesterolaemia: a common disease. (2016) (5)
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study (2020) (5)
New worldwide lipid guidelines (2015) (5)
Mendelian Randomization Study of ACLY and Cardiovascular Disease. Reply. (2020) (5)
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study (2020) (5)
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. (2022) (5)
Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. (2007) (5)
Undernutrition in adolescence and risk of cardiovascular disease. (2012) (5)
Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. (2020) (5)
Effect of Moringa oleifera root extract on penicillin-induced epileptic rats (2005) (5)
PROVE IT-TIMI 22 an Low-Density Lipoprotein Be Too Low ? he Safety and Efficacy of Achieving Very Low ow-Density Lipoprotein With Intensive Statin Therapy PROVE IT-TIMI 22 Substudy tephen (2005) (5)
Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society (2014) (5)
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia (2018) (5)
Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges (2019) (4)
Evolocumab and clinical outcomes in patients with cardiovascular disease. (2017) (4)
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. (2021) (4)
Biomarkers of radiation injury and response (2014) (4)
The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study (2021) (4)
Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. (2017) (4)
Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies (2020) (4)
Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid (2022) (4)
Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes. (2020) (4)
P5306The comparison of the lipid profile in the population of Poland between 2004, 2006 and 2015 based on the results of the LIPIDOGRAM cohort studies (2017) (4)
Intensive statin therapy for treating acute coronary syndromes (2006) (4)
INCLISIRAN AND CARDIOVASCULAR OUTCOMES: ANALYSES FROM ORION-11 (2020) (4)
Interleukin-1 revisited: further insights into its role in atherosclerosis and as a potential therapeutic target for treatment. (2014) (4)
Abstract 18484: Modest Potential Association Between Reductions in Lipoprotein(a) and Major Adverse Cardiovascular Events in the Phase 3 Trials of Alirocumab versus Control (2016) (4)
Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano? (2016) (3)
Costs Of Cardiovascular (Cv) Events In The United Kingdom (Uk) Using Real-World Data. (2015) (3)
Diabetes: Which risk engines should be used to assess patients with diabetes? (2009) (3)
Efficacy and Safety of Bempedoic Acid + Ezetimibe Fixed-Dose Combination in Patients at High CVD Risk and with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy (2019) (3)
Long-term mortality following acute myocardial infarction among those with and without diabetes: A systematic review and meta-analysis of studies in the post reperfusion era. (2016) (3)
Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations (2020) (3)
Effects of radiation on the reproductive system (2011) (3)
The Magnitude of Increased Cardiovascular (Cv) Risk Associated with Familial Hypercholesterolemia (Fh) for use in Economic Analyses. (2015) (3)
Cardiovascular Disease and its Risk Factors in Patients with Familial Hypercholesterolemia: A Systematic Review (2017) (3)
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm (2022) (3)
The power of lipid registries for cardiovascular disease prevention (2021) (3)
Efficacy, Safety And Pharmacokinetics Of Inclisiran By Renal Function (2019) (3)
Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease (2021) (3)
Biomarkers, C‐reactive proteins and statins in acute coronary syndromes (2007) (3)
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. (2017) (3)
Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimibe therapy on atherogenic and protective lipid factors: The accentuate trial (2016) (3)
Statins and risk of incident diabetes – Authors' reply (2010) (3)
The spoils of war and the long-term spoiling of health conditions of entire nations (2022) (3)
Lipid management: maximising reduction of cardiac risk. (2013) (3)
The role of Acorus calamus in the involvement of monoaminergic and electroencephalographic activities of amygdala kindled rats (2005) (3)
4945Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial (2019) (3)
Cardiac rehabilitation versus standard care after aortic aneurysm repair (Aneurysm CaRe): study protocol for a randomised controlled trial (2015) (3)
Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future (2021) (2)
FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALS (2020) (2)
Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia: pooled analyses from phase 3 trials (2020) (2)
Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11) (2020) (2)
6 MONTHLY INCLISIRAN AND ATHEROGENIC LIPOPROTEIN REDUCTIONS IN ORION-11 (2020) (2)
Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe? (2009) (2)
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI (2022) (2)
RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL (2016) (2)
TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. (2021) (2)
Time to change the SCORE? (2017) (2)
Toxicity of Radiation (2017) (2)
Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study (2021) (2)
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin (2019) (2)
Where to now in cardiovascular disease prevention. (2016) (2)
VIRTUAL HISTOLOGY INTRAVASCULAR ULTRASOUND FINDINGS PREDICT ADVERSE OUTCOME IN PATIENTS WITH CORONARY ARTERY DISEASE: THE VIVA (VH-IVUS IN VULNERABLE ATHEROSCLEROSIS) STUDY (2011) (2)
Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials (2020) (2)
P1699Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines? (2018) (2)
EFFECT OF INCLISIRAN ON LDL-C REDUCTION ACROSS DIFFERENT BACKGROUND LIPID LOWERING TREATMENTS: ANALYSES FROM ORION-11 (2020) (2)
EVALUATION OF LDL-C REDUCTIONS BY SIRNA TREATMENT WITH INCLISIRAN IN PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME OR NEITHER (2020) (2)
Abstract 18086: Rates of Cardiovascular Events in Patients Receiving High-Intensity Statin Therapy in the United Kingdom (2015) (2)
Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study (2021) (2)
Lipid lowering with inclisiran: a real-world single-centre experience (2022) (2)
World Heart Federation Cholesterol Roadmap 2022 (2022) (2)
Cardiovascular Disease Risk And Risk Factors Associated With Familial Hypercholesterolemia: A Systematic Review (2017) (2)
Ionizing radiation and radioactive materials in health and disease (2012) (2)
Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study (2022) (2)
of Statins in the Management of Acute Coronary Syndromes The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects (2011) (2)
Targeting PCSK9: Implications for basic science and upcoming challenges. (2019) (2)
American Heart Association’s Cholesterol CarePlan as a Smartphone-Delivered Web App for Patients Prescribed Cholesterol-Lowering Medication: Protocol for an Observational Feasibility Study (2019) (2)
BET PROTEIN INHIBITION AND COGNITION: A PRE-SPECIFIED SUBSTUDY OF THE BETONMACE PHASE 3 TRIAL EVALUATING APABETALONE IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROME (2019) (1)
EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS (2023) (1)
Abstract 13189: Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study (2018) (1)
Intensive glucose control and cardiovascular outcomes – Authors' reply (2009) (1)
864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED (2022) (1)
Inter-individual variability in LDL-C reductions with inclisiran – data from ORION-10 and ORION-11 (2020) (1)
BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS (2020) (1)
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial (2023) (1)
Long-Term Efficacy and Safety of Inclisiran in Patients with High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol (ORION-3): Results from the 4-Year Open-Label Extension of the ORION-1 Trial (2022) (1)
Underuse of coronary revascularization procedures. (2001) (1)
Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress (2022) (1)
INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions (2021) (1)
ACP Journal Club: statins do not reduce mortality in patients with no history of cardiovascular disease. (2010) (1)
Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58 (2020) (1)
Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis. (2020) (1)
Effect of inclisiran on haematological and immunological biomarkers: A Pooled analysis of ORION-9, -10 and -11 trial data (2021) (1)
Can we revive CETP-inhibitors for the prevention of cardiovascular disease? (2022) (1)
Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. (2023) (1)
Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. (2022) (1)
Echocardiographic diagnosis of a subvalvar aortic membrane (1996) (1)
185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials (2020) (1)
Abstract 15282: Individual Participant Meta Analysis of the Cardiovascular Safety of Taspoglutide Among Individuals with Diabetes (2012) (1)
post-partum defecatory dysfunction: a complex problem involving co-existing faecal incontinence and constipation : o37 (2014) (1)
ENDOTHELIAL FUNCTION ASSESSMENT AND MAJOR CARDIOVASCULAR OUTCOMES: AN UPDATED META-ANALYSIS (2012) (1)
175-OR: Effect of Alirocumab in Individuals with Type 2 Diabetes and High Triglycerides and Low High-Density Lipoprotein Cholesterol (2019) (1)
Cost-effectiveness of universal screening for familial hypercholesterolaemia (fh) at age 1-2 years (2018) (1)
Lipid Lowering in Coronary Artery Disease (2012) (1)
The DA VINCI study: is Ireland achieving ESC/EAS guideline–directed LDL-C goals? (2022) (1)
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease (2022) (1)
Abstract 16850: Effect of Alirocumab in Patients With Diabetic Dyslipidemia and Chronic Kidney Disease (2016) (1)
Alirocumab offers superior benefits to usual care in treating high-risk patients with type 2 diabetes (2020) (1)
CARAT: will infusing a pre-beta high-density lipoprotein mimetic (CER-001) regress coronary atherosclerosis? (2017) (1)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS (2017) (1)
FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia (2021) (1)
Do European patients with peripeheral arterial disease receive optimal lipid lowering therapy and achieve LDL-C goals? Results from the DA VINCI study (2020) (1)
Abstract 16427: Efficacy and Safety of Inclisiran According to Age: A Pooled Analysis of Phase III Studies (ORION 9, 10 and 11) (2020) (1)
Will genetic studies deliver the next generation of cardioprotective therapies? (2017) (1)
Rationale and Pathways Forward in the Implementation of Coronary Artery Calcium-Based Enrichment of Randomized Trials. (2021) (1)
Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. (2022) (1)
Lipid lowering therapy in primary and secondary prevention across Europe: Are LDL-C goals achieved? Results from the da vinci study (2020) (1)
Prevalence of anti-nuclear autoantibodies (ANA) in the general Polish population - analysis of the influence of sex and age on the variability of ANA. (2021) (1)
Abstract 16311: Efficacy and Safety of Inclisiran According to Sex: A Pooled Analysis of the ORION 9, 10 and 11 Trials (2020) (1)
Characteristics of adults with heterozygous familial hypercholesterolaemia stratified by gender: Preliminary analysis from the EAS FHSC global registry on over 36,000 cases of familial hypercholesterolaemia (2020) (1)
Hypercholesterolemia Among Premature Infarcts: Time to Start the Clock of Familial Hypercholesterolemia Assessment. (2019) (1)
Optimal goals for statin use in patients with coronary artery disease. (2005) (1)
RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALIROCUMAB OR EZETIMIBE IN THE PHASE 3 ODYSSEY TRIALS (2016) (1)
Edinburgh Research Explorer Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial (2017) (1)
siRNA to PCSK9 in patients with high cardiovascular risk and elevated LDL-C: the ORION 1 trial. (2017) (1)
Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia (2020) (1)
Precision medicine as the future of public health (2023) (0)
EFFICACY AND SAFETY OF INCLISIRAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A POOLED ANALYSIS FROM THREE PHASE 3 CLINICAL TRIALS (ORION-9, -10 AND -11) (2021) (0)
ESTIMATED CARDIOVASCULAR BENEFITS OF INCLISIRAN IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (2021) (0)
High-density lipoprotein cholesterol—new approaches (2011) (0)
Are Statins Effective in High-Risk Primary Prevention?—Reply (2010) (0)
Combined Exposure to both Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA (2019) (0)
459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither (2021) (0)
THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL (2020) (0)
Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at Very High Cardiovascular Risk in the United Kingdom: Results from a General Practice Population Study (2013) (0)
P5364Safety profile of bempedoic acid: pooled analysis of 4 phase 3 clinical trials (2019) (0)
P4608BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial (2019) (0)
Cardioprotective Therapies and Diabetes Risk: An Overview (2011) (0)
OP-EHEA170733 2546..2550 (2018) (0)
FindMyLipidClinic.com: A global Directory of lipid clinics and patient organisations to improve dyslipidemia care: FindMyLipidClinic.com (2022) (0)
dent diabetes between intensive-dose and moderate-dose statin allocation in these 219 cases. (2016) (0)
Characteristics And Risk Factor Burden Of Patients Receiving Lipid Modifying Therapy In The United Kingdom (2017) (0)
A systematic review and meta-analysis of the efficacy of medications directed against PCSK9 in familial hypercholesterolemia. (2021) (0)
Bempedoic Acid Efficacy and Safety in High CVD Risk Patients Treated With or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials† (2020) (0)
Effects of pitavastatin therapy on glucose, HBA1C and incidence of diabetes mellitus: A meta-analysis of randomized controlled clinical trials in non-diabetic individuals (2015) (0)
Review: intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes (2009) (0)
Left ventricular noncompaction. (2011) (0)
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. (2023) (0)
SP436DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES (2018) (0)
An Aid to Radiology for the MRCP (2000) (0)
TO001EFFECTS OF THE BET-INHIBITOR APABETALONE ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ACUTE CORONARY SYNDROME, ACCORDING TO PRESENCE OR ABSENCE OF CHRONIC KIDNEY DISEASE. A BETONMACE TRIAL REPORT (2020) (0)
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? (2021) (0)
Historical and Future Oral Lipid Modifying Therapy Market Size in Top Five European Countries (2016) (0)
Abstract 11516: Peripheral Neuropathy is an Independent Predictor of Cardiovascular Events Among Individuals With Diabetes Mellitus (2013) (0)
Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future". (2020) (0)
Favorable cognitive effects of the BET protein inhibitor apabetalone in patients 70 and older (2021) (0)
PCV100 Resource Use in Patients with Acute Coronary Syndrome - an Observational Study Across Secondary and Primary Care in a UK Population (2011) (0)
THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL (2022) (0)
P1512Assessment of absolute reductions in LDL-C associated with alirocumab therapy: results from across the Phase 3 ODYSSEY programme (2017) (0)
FHにおけるアンメット・ニーズ：見逃しの減少と早期からの積極的治療介入 (2016) (0)
Abstract 3076: Elevated levels of Placental Growth Factor (PlGF) and Long Term Risk in Patients with Acute Coronary Syndrome in PROVE IT-TIMI 22 (2006) (0)
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. (2023) (0)
Long-term mortality following acute myocardial infarction among those with and without diabetes: A systematic review and meta-analysis of studies in the post reperfusion era. Short title: Diabetes and long-term mortality post myocardial infarction (2016) (0)
Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial (2020) (0)
Omega-3 fatty acids in cardiovascular disease: re-assessing the evidence Panel members (2012) (0)
28 More Versus Less-intensive Platelet Inhibition in Acute Coronary Syndromes: A Meta-analysis of Randomised-Controlled Trials (2014) (0)
UK consensus position on the management of homozygous familial hypercholesterolaemia and the introduction of new agents (2014) (0)
FH ALERT: A feasibility study of a novel approach to identify patients with familial hypercholesterolemia (2020) (0)
Clinical Implications. (2018) (0)
Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies. (2023) (0)
Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk. (2021) (0)
Reduction in the risk of MACE with apabetalone in patients with recent acute coronary syndrome and diabetes according to NAFLD fibrosis score: exploratory analysis of the BETonMACE trial (2021) (0)
The year in cardiology: cardiovascular prevention /The year in cardiology 2019 (2020) (0)
Abstract 2256: Increased Monocyte Activation Detected By Serum Neopterin and Long-Term Risk in Patients with Acute Coronary Syndromes: Analysis From PROVE IT-TIMI 22 (2006) (0)
Lipid Modifying Therapy Treatment Patterns And Cholesterol Control After Cardiovascular Events In The United Kingdom. (2015) (0)
Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry (2022) (0)
Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register (2021) (0)
Long-Term Prognostic Value of Neopterin A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome Coronary Heart Disease (2007) (0)
POOLED SAFETY ANALYSIS OF INCLISIRAN IN 3,576 PATIENTS WITH APPROXIMATELY 10,000 PERSON YEARS OF EXPOSURE FROM 7 TRIALS (2023) (0)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN WOMEN: ANALYSES FROM THE ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL (2017) (0)
Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. (2023) (0)
Heterozygous familial hypercholesterolaemia in children: Preliminary analysis from the EAS FHSC global registry on over 7,900 children with familial hypercholesterolaemia (2020) (0)
Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials (2021) (0)
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. (2023) (0)
581-P: Remnant Cholesterol: Association to Components of the Metabolic Syndrome or Triglyceride-Glucose Index in the LUPS Cohort (2020) (0)
Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials (2020) (0)
Abstract 18813: Microvascular Complications Predict Cardiovascular Disease In Type 2 Diabetes: A Population Study (2016) (0)
AD1 - ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROSIS OR OTHER CARDIOVASCULAR RISK FACTORS TREATED WITH STATINS AND/OR EZETIMIBE (2018) (0)
APABETALONE (AN EPIGENETIC BET-INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE (2018) (0)
Edinburgh Research Explorer Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol (2020) (0)
Challenges in constructing genetic instruments for pharmacologic therapies (2020) (0)
Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes (2020) (0)
Evolocumab use in Europe: clinical guidelines vs. reimbursement thresholds – results from the HEYMANS study (2021) (0)
Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study. (2023) (0)
981 CARDIOVASCULAR RISK PROFILE ASSESSMENT AS REPORTED BY INVESTIGATORS AND BY ESC/EAS CRITERIA: EVIDENCE FROM SANTORINI STUDY (THE ITALIAN REALITY)) (2022) (0)
Abstract 3204: Assessment of Adiponectin and the Risk of Recurrent Cardiovascular Events: Observations from the PROVE IT-TIMI 22 Trial (2008) (0)
Aspirin to prevent incident cardiovascular disease: is it causing more damage than it prevents? (2012) (0)
Atherothrombotic residual risk in coronary and peripheral artery disease patients on guideline-recommended antiplatelet monotherapy: baseline preliminary results from the RESRISK study (2021) (0)
What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries (2020) (0)
From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society (2023) (0)
Premature Morbidity And Mortality Among Diagnosed And Potentially Undiagnosed Familial Hypercholesterolemia Patients In The General Population: An Observational Study Of Over 1.7 Million Health Records (2019) (0)
WHICH VIRTUAL HISTOLOGY INTRAVASCULAR ULTRASOUND PROPERTIES DISCRIMINATE BETTER BETWEEN STABLE ANGINA PECTORIS AND TROPONIN POSITIVE ACUTE CORONARY SYNDROME - ASSESSMENT OF PLAQUES OR ANALYSIS OF THE WHOLE CORONARY ARTERY VASCULATURE? (2010) (0)
†Efficacy and Safety of Inclisiran in Patients with Established Cerebrovascular Disease: Pooled Post hoc Analysis of the Phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials (2022) (0)
Alirocumab: an investigational treatment for hypercholesterolemia (2015) (0)
Statin therapy dose and risk of new-onset diabetes - Reply (2011) (0)
Hyperglycaemia and coronary heart disease: the meta picture (2009) (0)
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. (2023) (0)
Bempedoic Acid to Lower LDL Cholesterol - Safety and Efficacy. Reply. (2020) (0)
Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review. (2022) (0)
Abstract 13139: Fasting Triglycerides Are Independently Associated With Subclinical Atherosclerosis: The ELSA-Brasil Study (2015) (0)
Abstract 15790: Effects of an Investigational RNAi Therapeutic Targeting PCSK9 on Immunological and Hematological Parameters: A Safety Analysis From ORION-1 (2018) (0)
EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR ALIROCUMAB 300 MG EVERY 4 WEEKS IN INDIVIDUALS WITH TYPE 2 DIABETES ON MAXIMALLY TOLERATED STATIN THERAPY (2017) (0)
Prevalence and management of familial hypercholesterolaemia in the EUROASPIRE IV project (2015) (0)
Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65,229 Participants (2011) (0)
Abstract 11033: Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled Trials (2021) (0)
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins (2022) (0)
Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study (2022) (0)
Statin therapy for secondary prevention of coronary heart disease: an update (part 2) (2008) (0)
Statins and risk of incident diabetes Reply (2010) (0)
Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab (2016) (0)
Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans (2017) (0)
Diabetic microvascular triopathy, smoking, and risk of cardiovascular events - Author's reply. (2016) (0)
Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records (2019) (0)
Significance of perfusion of the infarct related coronary artery for susceptibility to ventricular tachyarrhythmias in patients with previous myocardial infarction. (1996) (0)
Statins for people at low risk of cardiovascular disease (2012) (0)
Abstract 14248: Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials (2020) (0)
Detection of atherosclerotic cardiovascular disease in ﬂ uences the perceived need for aggressive lipid management Atherosclerosis (2017) (0)
P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice (2019) (0)
Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses (2018) (0)
Cardiovascular risk factors in patients with and without a history of atherosclerotic cardiovascular disease in the SANTORINI study and estimation of risk (2022) (0)
Abstract 15054: Predictive Factors of the Magnitude of Response to Alirocumab Dose Increase in Patients With Dyslipidemia (2017) (0)
Abstract 14307: Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial (2020) (0)
Thyroxine replacement therapy and risk of myocardial infarction : a cautionary tale! (2008) (0)
Comprar An Aid to Radiology for the MRCP | Stanley Korenman | 9780632049127 | Wiley (2009) (0)
Abstract 3480: Neopterin Levels Improve Risk Prediction for Heart Failure Hospitalization Over and Above C-reactive Protein and B-type Natriuretic Peptide in the PROVE IT-TIMI 22 Study (2009) (0)
Genetic Variants Related to Combined Exposure to both Lower Low- Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA Network Open, E1-E11 (2019) (0)
Abstract 12268: Efficacy of Bempedoic Acid: A Pooled Analysis of 4 Pivotal Phase 3 Clinical Trials (2019) (0)
FASTING REMNANT LIPOPROTEIN CHOLESTEROL IS INDEPENDENTLY ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS: THE ELSA-BRASIL STUDY (2016) (0)
EFFECTS OF THE EPIGENETIC BET-INHIBITOR SMALL MOLECULE APABETALONE ON COGNITION IN PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE (2019) (0)
Aggressive statin therapy for acute coronary syndromes (2007) (0)
Alteration of serum monoamine level and brain electrical activity in stress and hypertension by Black tea (2007) (0)
Management of cardiovascular risk in patients with AAA in England: An analysis of 20,000 primary care records (2014) (0)
The need for a new classification of cholesterol lowering therapies (2017) (0)
BEDSIDE Prospective study of fasting and postprandial chylomicron triglyceride content and cardiovascular events in patients with stable coronary artery disease (0)
New versus old cardiometabolic markers of risk (2008) (0)
Author reply: Which risk engines are best to assess CVD risk in diabetes? (2010) (0)
High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry (2022) (0)
Abstract 16388: Efficacy and Safety of Early Dalcetrapib Treatment on Lipid Profile and Markers of HDL Functionality in Patients Hospitalized for an Acute Coronary Syndrome - The dal-ACUTE Study (2012) (0)
New Biomarkers of Cardiovascular Disease in Diabetes (2014) (0)
Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients (2022) (0)
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. (2023) (0)
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief? C oNTRoVERSIES I N C ARDIoVASCULAR M EDICINE (2015) (0)
Statin therapy for secondary prevention of coronary heart disease: an update (part 3) (2008) (0)
The role of Moringa oleifera epilepsy and its management (2016) (0)
What is the potential cardiovascular risk reduction associated with achieving LDL-C levels recommended in the ESC/EAS guidelines for very high-risk patients? Data from 18 European countries (2020) (0)
PCV23 Clopidodgrel and Statin Prescribing Patterns in ACS Patients – an Observational Study Using Linked Secondary and Primary Care Data in a UK Population 2003-2009 (2011) (0)
Relationship of non-HDL-cholesterol levels and goal attainment with triglycerides and remnant lipoproteins in a nationwide survey of over 2600 diabetic subjects with cardiovascular disease (2015) (0)
The year in cardiology: cardiovascular prevention. The year in cardiology 2019. (2020) (0)
Alirocumab Add-on Therapy Versus Control in Individuals with Type 2 DM and ASCVD: ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN (2018) (0)
Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trials† (2020) (0)
Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records (Preprint) (2019) (0)
Contemporary Treatment Gaps in the Implementation of Ldl Cholesterol Control Among High- And Very High-Risk Patients in Europe between 2020–2021 – The Multinational Santorini Study (2022) (0)
P6238Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials (2017) (0)
THE EFFECT OF INCLISIRAN IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION: A POST HOC POOLED ANALYSIS FROM THE ORION-10 AND ORION-11 RANDOMIZED CONTROLLED TRIALS (2022) (0)
Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia. (2017) (0)
Lipid-independent Pleiotropic Effects Lipid-independent Pleiotropic Effects of Statins in the Management of Acute of Statins in the Management of Acute Coronary Syndromes Coronary Syndromes (2007) (0)
Statin therapy for secondary prevention of coronary heart disease: an update (2008) (0)
Ldl-C Lowering Among Patients With Ldl-C Above 4.9 Mmol/L And Features Suggesting A Genetic Vulnerability To Cardiovascular Disease: Analyses From The 4s Trial (2019) (0)
Heterozygous Familial Hypercholesterolaemia in Specialist Centres in South Africa, Australia and Brazil: Importance of Early Detection and Lifestyle Advice (2018) (0)
The Safety and Clinical Utility of Dobutamine Stress Echocardiography among Octogenarians (2016) (0)
Correction to: Role of Bempedoic Acid in Clinical Practice (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kausik Kumar Ray?

Kausik Kumar Ray is affiliated with the following schools:

University of Sheffield
Imperial College London
University of Calcutta
University of Cambridge

Kausik Kumar Ray's Academic­Influence.com Rankings

Kausik Kumar Ray's Degrees

Why Is Kausik Kumar Ray Influential?

Kausik Kumar Ray's Published Works

Published Works

What Schools Are Affiliated With Kausik Kumar Ray?

Kausik Kumar Ray's AcademicInfluence.com Rankings